History

oncology
pain
dependence
respiratory-tract
1952

How it all began

The Austrian company Mundipharma Ges.m.b.H. is part of a privately owned network of independent associated companies that operates internationally. The founding history dates back to 1952, when the two brothers Mortimer D. Sackler, M.D. and Raymond R. Sackler, M.D. bought the US-based company Purdue. Blessed with the necessary pioneering spirit, the owners developed a network of independent associated companies that is currently represented in numerous European countries and worldwide. The tradition of a family business has propagated over the years and is still reflected, e.g. in long-term and trusting relationships.

1973

The first steps in Austria

In 1973, the Austrian branch was opened in Vienna. The first economic success was realised shortly after founding – in the 1970s, Mundipharma started with products that are used in the fields of disinfection and wound hygiene/healing. All products of the brand Betaisodona® include iodine, an agent commonly used to treat wounds. In one particular manufacturing method, iodine is optimised to a larger structure (povidone–iodine complex) so that the active agents are released as needed.

1985

“Pain specialist” research focus

An Example of Mundipharma’s Research & Development activities is the area of pain therapy. In 1985, with the introduction of the first strong prolonged-release opioids, Mundipharma revolutionised the treatment of pain. Prolonged-release means that the active agent is released slowly over a certain period of time. This has advantages – medications do not have to be taken as frequently, and tolerability is improved.

Both patients and therapists benefited from the improved prolonged-release products that followed. In the current product portfolio there are 10 high-quality pharmaceuticals used to treat severe pain.

1999

Special topic: addiction

In 1999, Mundipharma expanded into another important therapeutic field. As the first company in Austria, Mundipharma received approval for a pharmaceutical designed to treat opioid dependence. The preparation of this medication was a milestone within the existing therapeutic options for this patient group. Opioid dependence is a serious and chronic psychiatric disorder. Affected patients are often exposed to social hostility, and it is difficult for them to receive the appropriate support and acceptance.

Mundipharma currently has two pharmaceuticals that facilitate the daily lives of opioid dependent patients. Mundipharma is also promoting a dialogue between physicians, pharmacists, and social institutions that deal with this issue.

2004

A focus on oncology

Since 2004, Mundipharma has been involved in the area of cancerous diseases. Every year in Austria, more than 35,000 people develop cancer. Cancer is the second most common cause of death following cardiovascular diseases. Complex changes in body cells lead to neoplastic diseases. Mundipharma provides two chemotherapeutic agents, which are primarily used in the field of hemato-oncology (tumour diseases of the hematopoietic and lymphatic systems).

2012

Vienna as a hub for Eastern Europe

Since 2012, Mundipharma Ges.m.b.H. has full responsibility for commercial agreements affairs in the representative offices in Eastern Europe. Business activities are currently being pursued in Poland, the Czech Republic, Slovakia, Romania, Bulgaria, and Russia. An expansion into other Eastern European countries is planned. In the Baltic countries, Croatia, Slovenia, and Hungary Mundipharma has established corporate agreements with local partners.

Vienna serves as a management hub for the marketing and distribution of Mundipharma pharmaceuticals within a large territory and thus has an important strategic role within the Mundipharma network of independent associated companies.

2014

Direction respiratory

Mundipharma extends the product-portolio by launching a pharmaceutical for the treatment of respiratory disease asthma. Thus Mundipharma opened a new business unit for the company! With the introduction of a combination product with 2 proven ingredients the treatment options for patients who suffer from asthma are extended.